semaj83/ctmatch_classification huggingface dataset:
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Bipolar Disorder Must have Bipolar disorder as confirmed by the Mini Neuropsychiatric Interview (MINI) Must be age 50 or older Must have sub-optimal response to current psychotropic management including at least one of the following Behaviors and symptoms of irritability, agitation, mood liability or diminished ability to interact with others in their place of residence Diminished ability to take care of basic personal needs in their place of residence due to symptoms of bipolar disorder Intolerance to current psychotropic medications; and Must live in the Northeast Ohio area  An unstable medical illness, or a medical illness, which in the opinion of the study investigators, is likely to affect the outcome of the study DSM-IV substance dependence (except nicotine or caffeine) within the past 3 months; or Receiving carbamazepine
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 15.0-29.0,  Bipolar Disorder Schizoaffective Disorder Male and female patients aged 15 to 29 Experiencing a first episode psychosis Meet DSM-IV for bipolar either manic or mixed episode, or schizoaffective disorder manic episode Minimum score of 20 on the YMRS Written informed consent to participation  Patients at immediate risk of committing harm to self or others Use of neuroleptics or mood-stabilisers in the two months preceding admission to EPPIC Organic mental disease, including mental retardation History of clinically significant illness (liver or renal insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological or metabolic disturbances) Clinically relevant biochemical or hematological abnormalities Pregnant or lactating woman History of epilepsy History of severe drug allergy or hypersensitivity Non fluency in English
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Obesity Are men or women, between the ages of 19 and 65, inclusive Have a diagnosis of any type of bipolar disorder or any type of psychotic disorder based on structured diagnostic interview (MINI) Are currently outpatients or inpatients and taking a neuroleptic or mood stabilizer medication (listed below) for the past 6 months, and on a stable dose for the past 2 months Have a body mass index > 25 No substance use disorder in the past 2 months (except for nicotine or caffeine) Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study such as a barrier method, hormonal contraceptive, or surgical sterilization (females only). All women of childbearing potential must have a negative pregnancy test before beginning study medication Are able to swallow the capsules whole Are willing and able to follow Investigator instructions and study procedures, and report adverse events Not currently actively suicidal or homicidal No use of topiramate within the last 6 months  Clinically significant renal or hepatic disease History of acute intermittent porphyria, glucose-6phosphate dehydrogenase deficiency or hemolytic anemia Allergy to zonisamide or sulfonamides Have clinically unstable cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease Have laboratory test results that, in the opinion of the Investigator, are clinically significant abnormalities Require treatment with any medication (e.g., carbonic anhydrase inhibitors) that might interact adversely with, or obscure, the action of the study drug Are pregnant or lactating (females only) Have a history of nephrolithiasis Refuse to give informed consent Have previously enrolled in this study or previously been treated with zonisamide
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Binge Eating Disorder Associated With Obesity Patients will meet DSM-IV for BED for at least the last 6 months. These are as follows Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following: (1) eating, in discrete period of time (eg, within any two hour period), an amount of food that is definitely larger than most people would eat in a similar period of time under similar circumstances and (2) a sense of lack of control over eating during the episode (eg, a feeling that one cannot stop eating or control what or how much one is eating) The binge eating episodes are associated with at least three of the following Eating much more rapidly than normal Eating until uncomfortably full Eating large amounts of food when not feeling physically hungry Eating alone because of being embarrassed by how much one is eating Feeling disgusted with oneself, depressed, or feeling very guilty after overeating Marked distress regarding binge eating The binge eating occurs, on average, at least two days a week for six months  Have current body mass index < 30kg/m2 Women who are pregnant or lactating and women of childbearing potential who are not taking adequate contraceptive measures. If there is a possibility a female subject might be pregnant, a pregnancy test will be performed. (All women of childbearing potential will have a negative pregnancy test before entering the study.) Subjects who are displaying clinically significant suicidality or homicidality Subjects who are displaying a current clinically unstable depressive disorder (e.g., HAM-D > 21) A current or recent (within 6 months of the start of study medication) DSM-IV diagnosis of substance abuse or dependence A lifetime history of a DSM-IV bipolar disorder or dementia History of a personality disorder (eg, schizotypal, borderline, or antisocial) which might interfere with assessment or compliance with study procedures Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease which could interfere with diagnosis, assessment, or treatment of binge eating disorder. Patients should be biochemically euthyroid prior to entering the study History of seizures, including febrile seizures in childhood History of clinically significant nephrolithiasis
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 13.0-75.0,  Bipolar Disorder In order to be included in the study patient must meet A, C, D, E, F, G plus any 1 of the 3 listed in section B A. Patients meeting DSM-IV diagnosis of bipolar disorder, I or II Patients meeting DSM-IV diagnostic for a manic/hypomanic episode with the simultaneous presence of (or rapid alteration within minutes) of at least three DSM-IV depressive symptoms excluding psychomotor agitation or Patients meeting DSM-IV symptomatic for a hypomanic/manic episode for a period of 2 days or longer, with the simultaneous presence of (or rapid alteration within minutes) of at least three DSM-IV depressive symptoms excluding psychomotor agitation or Patients meeting DSM-IV for a depressive episode associated with at least three DSM-IV manic/hypomanic symptoms C.MADRS of ≥14 D.YMRS of ≥ 14 E. Age 13years to 75 years F. Male or female G. Outpatient  illness precluding the use of LAM Alcohol/drug dependence in the past one month patients with a history of a rash on LAM CNS neoplasms, demyelinating diseases, degenerative neurological condition or active CNS infection history of seizure, known EEG with frank paroxysmal activity, known CT of brain showing gross structural abnormalities, cerebral vascular disease by history or structural brain damage from trauma patients currently taking LAM
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Age above 18 is preceded by an affective episode requiring hospitalisation or outpatient drug treatment (index episode) which can be a manic episode (ICD-10 research criteria), a depressive episode of at least moderate degree (ICD-10 research criteria) or a mixed manic state (manic episode with at least additional three ICD-10 depressive symptoms except for difficulties with concentration or thinking, agitation or dyssomnia). The episode can be with or without psychotic symptoms including Schneiderian first-rank symptoms or bizarre delusions as long as the psychotic symptoms do not occur outside the affective episode No more than 12 months may pass between the onset of the index episode (or admission if that is the case)and date of randomisation (in order to ensure a current risk of relapse as well as reliable psychopathological information) Besides the index episode, at least one previous episode must have occurred within the last five years which meets the mentioned in point number two above. This episode may not necessarily have led to hospitalisation. Two episodes are separated by at least two months without significant symptoms or change in polarity (depression to mania/mixed mania or vice versa) At least one manic episode (or mixed manic episode) within the last 5 years  Contraindications to the protocol drugs Severe somatic disease, e.g. epilepsy, which may interfere with study treatment or effect evaluation Pregnancy (or risk of pregnancy) Subject has prior to randomization received prophylactic treatment with lithium or lamotrigine conducted adequately in the sense of sufficient time and dose and ensuring compliance, and experienced a definite lack of prophylactic effect An ICD-10 diagnosis of abuse within the last year with a subsequent risk of protocol violation. Therefore, subjects with a secondary abuse can often be included in the study Anticipated protocol violation for other reasons No written informed consent from the subject can be obtained The subject has previously been randomised in the study
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Obesity Age 18-65 years; BMI 30-50  Secondary obesity; Significant cardiovascular disease; Stroke, seizure disorder or other significant neurological disease; Significant liver or gallbladder disease; Significant renal disease or history of kidney stones; HIV positive status; Diabetes mellitus; Untreated or unstable hypothyroidism Malignancy in the past 5 years; Concomitant medications that cause significant weight gain or weight loss; Concomitant use of prescription or OTC weight loss medications; Had bariatric surgery or planning surgery in the next 1 year; Weight change of more than 4 kg in the past 3 months; Suicidal subjects; Major depression in the past 6 months; History of psychosis, bipolar disorder, or severe personality disorders; Subjects taking antipsychotics or mood stabilisers; Alcohol or substance abuse in the past 6 months; Currently taking zonisamide or other antiepileptic drugs; History of hypersensitivity to zonisamide or sulfonamides; Pregnant or planning pregnancy in the next year, or breastfeeding; Severe physical disability; Current participation in a commercial weight loss program or planning to participate; Currently following low-carbohydrate, high protein, high fat diet; Use of investigational medications or devices (current or past 4 weeks)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Binge Eating Disorder Obesity Patients will meet DSM-IV-TR for BED for at least the last 6 months, determined by the Structured Clinical Interview for DSM-IV-TR (SCID) (61) and supported by the Eating Disorder Examination (EDE) (62). These are as follows Recurrent episodes of binge eating. An episode of binge eating is characterized by both of the following eating, in discrete period of time (e.g., within any two hour period), an amount of food that is definitely larger than most people would eat in a similar period of time under similar circumstances a sense of lack of control over eating during the episode (e.g., a feeling that one cannot stop eating or control what or how much one is eating) The binge eating episodes are associated with at least three of the following eating much more rapidly than normal eating until uncomfortably full eating large amounts of food when not feeling physically hungry eating alone because of being embarrassed by how much one is eating feeling disgusted with oneself, depressed, or feeling very guilty after overeating  Have current body mass index < 30 kg/m2 Women who are pregnant or lactating and women of childbearing potential who are not taking adequate contraceptive measures. (All women of childbearing potential will have a negative pregnancy test before entering the study.) Subjects who are displaying clinically significant suicidality or homicidality Subjects who are displaying a current clinically unstable depressive or bipolar disorder, defined as a Montgomery Asberg Depression Rating Scale (MADRS) (63) > 24 or a Young Mania Rating Scale (YMRS) (64) > 8 A current or recent (within 6 months of the start of study medication) DSM-IV-TR diagnosis of substance abuse or dependence A lifetime history of a DSM-IV-TR psychotic disorder or dementia History of a personality disorder (e.g., schizotypal, borderline, or antisocial) which might interfere with assessment or compliance with study procedures Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease which could interfere with diagnosis, assessment, or treatment of binge eating disorder. Patients should be biochemically euthyroid prior to entering the study History of seizures, including febrile seizures in childhood Subjects requiring treatment with any drug which might interact adversely with or obscure the action of the study medication (e.g., stimulants, sympathomimetics, antidepressants, carbonic anhydrase inhibitors, anti-obesity drugs)
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bipolar Disorder Anxiety Disorder Subjects must be 18 years of age or older Subjects must have lifetime bipolar I, II, or NOS disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria Subjects must have lifetime panic disorder or generalized anxiety disorder (GAD) as defined by DSM-IV (except clause "does not occur exclusively during a mood disorder" of Criterion F for GAD)  Subjects' bipolar symptoms must be no more than moderately severe, defined as a CGI-BP < 4 Subjects' anxiety symptoms must be at least moderately severe, defined as a CGI-S > 4 Subjects must not be receiving mood stabilizing, antidepressant, antipsychotic, or anxiolytic medication for > one week prior to baseline. Patients receiving fluoxetine or depot antipsychotics should be off these medications for > four weeks prior to baseline Subjects or their legally authorized representative must sign the Informed Consent Document after the nature of the trial has been fully explained If female, subjects must be postmenopausal surgically incapable of childbearing  Subjects who do not have lifetime bipolar disorder by DSM-IV-TR (text revision) criteria Subjects who do not have lifetime panic disorder or generalized anxiety disorder by DSM-IV-TR criteria Subjects who are receiving treatment with an antimanic or mood stabilizing medication (lithium, valproate, carbamazepine, or an antipsychotic), and in the investigators' judgment, require ongoing treatment with that medication Subjects whose bipolar symptoms are presently more than moderately severe (CGI-BP > 5) Subjects whose anxiety symptoms are presently less than moderately severe (CGI < 3) Subjects with clinically significant suicidal or homicidal ideation Subjects with current psychotic symptoms Subjects with a current DSM-IV Axis I diagnosis of delirium, dementia, amnesia, or other cognitive disorders; a DSM-IV diagnosis of a substance dependence disorder within the past six months; or a lifetime DSM-IV psychotic disorder (e.g., schizophrenia or schizoaffective disorder) Subjects with serious general medical illnesses including hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, or hematologic disease as determined by the clinical judgment of the clinical investigator. Subjects with hypo or hyperthyroidism unless stabilized on thyroid replacement > 3 months
Patient description: A 26-year-old obese woman with a history of bipolar disorder complains that her recent struggles with her weight and eating have caused her to feel depressed. She states that she has recently had difficulty sleeping and feels excessively anxious and agitated. She also states that she has had thoughts of suicide. She often finds herself fidgety and unable to sit still for extended periods of time. Her family tells her that she is increasingly irritable. Her current medications include lithium carbonate and zolpidem.

Clinical trial eligibility criteria: eligible ages (years): 21.0-64.0,  Insomnia MAJOR Must experience sleep disturbances at least 3 nights/week, based on historical data Must meet the diagnostic requirements for Major Depressive Disorder Must have QIDS-SR16 score between 6 and 15 Must be either newly diagnosed or show symptoms of relapse/recurrence of depression while not on medication Age 21-64, inclusive Women must use a medically acceptable form of contraception (steroidal contraceptive, double-barrier, or intra-uterine device) during the entire study period, or: be surgically sterilized, post-menopausal, agree to use double-barrier contraception throughout the study period, or must have a negative urine pregnancy test prior to randomization Subject must be stabilized on all ongoing long-term medication therapy for at least 28 days prior to screening visit MAJOR  Severity of depressive episode had been rated as "severe" or "severe with psychotic features." History of a suicide attempt or suicidal ideation History of mania, manic episode or bipolar disease Currently using a benzodiazepine or SSRI or more than 2 days of use within the 28 days preceding randomization Use of prescription and non-prescription sedative drugs given for the purpose of sleep induction or to relieve jet lag Any abnormal pre-study laboratory values that require clinical intervention Prior failure to respond to escitalopram therapy for depression Current depressive episode requiring inpatient hospitalization Shift work or requirement for a regular change in sleep schedule by at least six hours within the previous 28 days History of drug addiction, alcoholism, or drug abuse